In previous studies (1, 4) , a method was developed for the quantitative recording of the lysis of thrombi and emboli produced with I'31-labeled fibrinogen. Using this method, the in vivo fibrinolytic activity of human and bovine plasmin was demonstrated (2) . Other proteolytic enzymes (crude pancreatic protease, trypsin, carboxypeptidase, papain and ficin) were ineffective in maximal tolerated doses (1, 3, 4) . Literature on the therapeutic use of proteolytic enzymes has been reviewed (1, 2) . In all previous experiments, treatment was started one-half hour after forming labeled clots in the experimental animals. The question arose whether plasmin treatment would be effective in dissolving organized clots and whether there is a correlation between degree of organization and plasmin-induced lysis. The preparations referred to as "plasmin" in this study actually contain a variety of enzymatic activities; they are fibrinolytic, proteolytic and are able to activate the fibrinolysin system. Presumably they represent a mixture of plasmin, plasmin-activator and free streptokinase. It is difficult to ascribe therapeutic activity to any one of these components. The purpose of these experiments is to study therapeutic indications and conditions for the preparations currently undergoing clinical trial. Labeled clots were produced in several veins of dogs at various time intervals. At the time of treatment, these clots were of various ages. Dif disappearance of radioactivity and by histopathologic study.
MATERIALS AND METHODS
Materials and methods were similar to those described in previous studies (1) . Under aseptic conditions, I3"-labeled purified bovine fibrinogen was introduced through side branches into isolated segments of veins of dogs and clotted with the aid of thrombin.
Semi-constricting aluminum wire ligatures were placed proximal to the clots and artery clamps isolating the segment were released one-half hour after clot formation. Radioactivity over the area was recorded with the aid of a specially constructed lead shield, a scintillation counter, an analytical radiation rate meter, and an Esterline recorder.
Mongrel dogs, 10 to 16 Kg. in body weight, were used. At the time of the beginning of treatment, the clots varied in age from 30 minutes to Patent 2, 666, 729) . We found that when lyophilized samples of the above material were diluted with increasing volumes of physiological saline, fibrinolytic activity first increased, then decreased. Such bellshaped dilution versus activity curves could be duplicated by adding excessive amounts of streptokinase to plasminogen prepared by the Kline method. This was interpreted as indicating that the preparation used in this study contained a considerable amount of free streptokinase. It is known that most batches of streptokinase are poor activators of dog plasminogen. On the other hand Sherry, Titchener, Gottesman, Wasserman, and Troll have shown (8) that streptokinase-activated human plasmin preparations may activate dog plasminogen. It is presently a matter of controversy whether this effect of streptokinaseactivated human plasmin is due to the presence of "activator" (9), or to the activating ability of a hypothetical plasminogen-streptokinase complex (10, 11), or a plasminstreptokinase complex (4, 11) .
Blood samples were taken before, and at various time intervals after, plasmin injections for hematological and biochemical analyses as in previous studies (14) . Prothrombin time is reported as clotting index: the ratio of the prothrombin time prior to treatment to the prothrombin time during and after plasmin administration. In most experiments as in previous studies (1-4) prothrombin time was also determined after adding bovine fibrinogen, so as to eliminate the effect of fibrinogenopenia on prothrombin time determinations. Figure 1 shows an experiment in which a dog with one-half hour, one, two and three day old clots was treated with daily injections of 30 plasmin units (Loomis) level used, clots three days of age or older can not effectively be dissolved with human plasmin.
RESULTS

Clot lysis
Histopathologic findings
The histological findings were not uniform throughout the length of a clot. Despite this it was possible to grade the clots histologically and it was found that the histological picture correlated closely with their known age. The most important factor in grading was the degree of endothelial and fibroblastic activity and subsequent vascularization and fibrosis. The ends of the clot and spaces where the clot did not adhere firmly to the vessel wall were largely covered with end'othelium by the third day ( Figure 3 ) and about this time a few fibroblasts were occasionally present in the substance of the clot (Figure 4 ). Vascular spaces were formed soon after this ( Figure 5 ). By the tenth day all clots were fully vascularized and many were only partially attached to the vessel wall with blood flowing around them ( Figure 6 ). A second factor in grading was the change in the clot itself from the early mixture of fibrin and red cells to a more homogeneous mass from which the red cells gradually disappeared. Van Giesen stain revealed no collagen formation before the tenth day.
It was not possible to distinguish the clots which had received plasmin therapy after three or more days of existence from the control clots of similar age. Where treatment was given earlier, the clot appeared to be less advanced than expected at the time of removal. In some vessels where complete disappearance of the original isotopically-labeled fibrin structure was indicated by measurement of radioactivity, histologic examination revealed the presence of relatively fresh nonlabeled clots. It seemed probable that lysis of the original clot had been followed by formation of a fresh thrombus. Control clots of the same age showed little decrease of radioactivity levels. A Resistance to lysis is apparent from the observation that most of the fibrinolytic effect is obtained within 24 hours after the first injection of plasmin, the remaining portions of the clot exhibiting less and less lysis during the subsequent days of treatment (2) . It was found that the ability of plasmin at a dose level of 30 plasmin units (Loomis) per Kg. to dissolve a clot is closely correlated with the degree of organization of the clot; the older the clot, the less lysis. It may be significant that even by the third day, most of the free edges of the clot were covered with a layer of endothelial cells (see Figure 3) . No fibrin clot. In addition, increased density of the fibrin may also impair the effect of plasmin.
The above factors may explain resistance to lysis, but are certainly inadequate to account for the resistance toward biochemical and hypotensive changes. A study of changes in antiplasmin levels and antiplasmin antibody formation is presently under way. Results to date indicate that although chronic treatment with plasmin will induce fluctuations in these factors, they are insufficient to explain the degree of resistance encountered.
From the therapeutic point of view, it appears that acute thrombo-embolic disorders present better indications for plasmin therapy than chronic conditions. Payling-Wright (14) has suggested the possibility that cortisone given simultaneously with anticoagulants may delay organization of clots and increase the rate of recanalization of thrombosed vessels in rabbits. On the other hand, there are indications that cortisone may increase antiplasmin production or activity thus decreasing normal fibrinolytic activity of the blood (15) .
After successful lysis of acute clots, reformation was observed in spite of continued treatment with plasmin. The experimental procedure called for opening the wound daily and inserting a lead shield and scintillation counter in the area. This obviously resulted in some degree of trauma and represented a possible source of infection despite daily administration of antibiotics. In addition, inflammatory reactions might have contributed to thrombus formation. These new clots were nonradioactive and were detected only upon autopsy. The fact that they did not lyse during daily treatment with plasmin (although they were fresh, unorganized clots) may be an expression of the general resistance developed toward plasmin as discussed above. Under most clinical conditions, stimuli for clot reformation are undoubtedly less than in the experimental arrangement reported here. The possibility of clot reformation after successful fibrinolytic therapy should be considered, particularly if a) the conditions originally responsible for clot formation still persist, and b) .the temporary presence of the clot caused additional injury to the vessel wall.
CONCLUSIONS
Venous clots were produced with I131-labeled fibrinogen in dogs at various time intervals. Five daily treatments with 30 plasmin units (Loomis) per Kg. of human plasmin completely lysed clots less than three days old, but did not affect those older than three days. Histologic examination revealed that three days after formation, the clot is already largely separated from the blood stream by a layer of endothelial cells which may prevent plasmin from reaching the clot. Increased clot density may also be a factor in the clot becoming resistant to treatment.
In some instances, although the original radioactive clot completely disappeared, reformation of new, nonradioactive thrombi took place. Trauma might have been a major cause of this phenomenon. Reformation of the clot occurred in spite of daily administrations of plasmin. This may be related to the developing resistance of the animal to this agent as shown by decrease in changes of the fibrinogen levels, clotting index and blood pressure response (2, 4, 16) .
On the basis of these findings, it seems that better therapeutic results may be expected from intravenous treatment with plasmin in acute rather than chronic thromboembolic disorders. In the latter, results would appear to depend on the degree of organization of the clot.
